MarginsXMarginsX
Home › Markets › Health Care › PRGO

Perrigo Company plc (PRGO)

PRGO trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$16.18
-0.37% on the day
Market cap
$2.2B
Mid cap
Revenue · 2025
$4.3B
-2.8% on 2024
Net income · 2025
-$1.4B
-33.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1585364/000158536426000009/0001585364-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPRGO on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001585364
SEC industry codePharmaceutical Preparations
Incorporated inIreland

Financials · 2025

LineValue
Revenue$4.3B
Net income-$1.4B
Operating income-$1.1B
Net margin-33.5%
Operating margin-26.4%
Revenue growth-2.8%
Cash$531.6M
Total assets$8.5B
P/E (computed)Net income was not positive
P/S (computed)0.5×

Warning signs

Cash runway
Cash-flow positive
$436.6M cash at September 26, 2026
Share count, 1 year
+0.9%
2025-10-31 to 2026-10-30 · +2.4% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$106K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$436.6M cash; operating cash flow $60.1M a quarter.Report 2026-09-26
Shares outstanding138,801,872 (2026-10-30); 137,624,009 a year earlier; 135,506,489 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2024-12-16
AuditorErnst & Young LLP, Grand Rapids, Michigan, United StatesPCAOB Form AP 2026-03-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $106K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-26
$988.6M-$27.5M$96.2M$436.6M$3.3B$4.1B10-Q 2026-11-04
Q2 2026
2026-06-27
$1.0B$74.5M$82.6M$399.7M$3.3B$4.1B10-Q 2026-08-05
Q1 2026
2026-03-28
$969.2M-$398.6M-$113.6M$357.2M$3.6B$4.2B10-Q 2026-05-06
Q4 2025
2025-12-31
$1.1B-$1.4B$175.4M$531.6M$3.6B$4.3B10-K 2026-02-26
Q3 2025
2025-09-27
$1.0B$7.5M$51.7M$432.1M$3.6B$4.3B10-Q 2026-11-04
Q2 2025
2025-06-28
$1.1B-$8.4M$75.9M$454.2M$3.7B$4.3B10-Q 2026-08-05
Q1 2025
2025-03-29
$1.0B-$6.4M-$64.5M$409.9M$3.6B$4.3B10-Q 2026-05-06
Q4 2024
2024-12-31
$1.1B-$44.5M$312.6M$558.8M$3.6B$4.4B10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-09-13
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-03

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.5%
1 month+5.7%
3 months+26.6%
Year to date+16.7%
1 year+16.2%
From 52-week high-4.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PHVSPharvaris N.V.$32.44-2.76%$2.3B
PBHPrestige Consumer Healthcare Inc.$48.00+3.92%$2.3B
LKFTLakefront Biotherapeutics$34.79+2.38%$2.3B
NAMSNewAmsterdam Pharma Company N.V.$19.46-3.38%$2.3B
PVLAPalvella Therapeutics Inc.$144.60-5.17%$2.1B
BHVNBiohaven Ltd. Common Shares$13.80-0.14%$2.1B
IMNMImmunome Inc.$17.61-6.18%$2.1B
RCUSArcus Biosciences Inc.$16.86-3.27%$2.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier